Beam Therapeutics Reports Q2 2026 Results, Doses First Patient in Pivotal BEAM-302 Trial, and Completes Risto-cel Dosing
BEAM sits 63% above its 52-week low of $15.6.
Summary
Beam Therapeutics announced Q2 2026 financial results and multiple clinical milestones, including the first patient dosed in the pivotal BEAM-302 trial for AATD and completion of dosing in the risto-cel BEACON trial for sickle cell disease, with a BLA submission expected by year-end 2026.
Key Events · Earnings and Guidance · BEAM
-
First Patient Dosed in Pivotal BEAM-302 Trial
Beam dosed the first patient in the global pivotal cohort of the Phase 1/2 trial for BEAM-302 in AATD, designed to support a potential accelerated approval path in the U.S.
-
Risto-cel Dosing Complete, BLA Submission Expected Year-End 2026
Dosing is complete for all adult and adolescent patients in the Phase 1/2 BEACON trial of risto-cel in sickle cell disease; Beam expects to submit a U.S. Biologics License Application as early as year-end 2026.
-
Updated BEAM-302 Data Selected for Late-Breaking ERS Presentation
Detailed and updated clinical data for BEAM-302 will be presented in a late-breaking oral session at the European Respiratory Society Congress, September 5-9, 2026.
-
BEAM-304 IND Cleared, Clinical Start-Up Underway
Following FDA clearance of the IND for BEAM-304 in PKU, Beam has initiated clinical trial start-up activities for the planned Phase 1/2 trial.
Analysis · BEAM · Life Sciences
Beam Therapeutics delivered a quarter of significant clinical execution alongside its Q2 2026 financials. The first patient dosed in the global pivotal cohort for BEAM-302 in AATD marks a major step toward a potential accelerated approval, while completing dosing in the BEACON trial for risto-cel in sickle cell disease puts the company on track for a BLA submission as early as year-end 2026. With $1.2 billion in cash and a runway into mid-2029, Beam is well-funded to advance these programs through key catalysts, including updated BEAM-302 data at the ERS Congress in September. The net loss widened to $122.7 million, but the clinical progress and regulatory milestones overshadow the financials, reinforcing the company's position as a leader in precision genetic medicines.
At the time of this filing, BEAM was trading at $25.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $15.60 to $38.26. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.